Download PDF
CC BY-NC-ND 4.0 · International Journal of Practical Otolaryngology 2023; 06(01): e1-e6
DOI: 10.1055/s-0043-1770367
Original Article

Diagnostic Rate of Malignant Lymphoma Using Soluble Interleukin 2 Receptor Levels in Patients with Cervical Lymphadenopathy

Kiyomi Hamaguchi
1   Department of Otorhinolaryngology—Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan
,
Yota Tobe
2   Department of Otorhinolaryngology—Head and Neck Surgery, Kyoto University Hospital, Kyoto, Japan
,
Tadashi Ikenaga
3   Department of Head and Neck Surgery, Nara Prefectural General Medical Center, Nara, Japan
,
Tetsuhiko Michida
1   Department of Otorhinolaryngology—Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan
,
Shinji Takebayashi
4   Department of Otorhinolaryngology, Shiga General Hospital, Shiga, Japan
,
Keizou Fujiwara
1   Department of Otorhinolaryngology—Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan
,
Yasushi Naito
1   Department of Otorhinolaryngology—Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan
,
Shogo Shinohara
1   Department of Otorhinolaryngology—Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background and Objectives Cervical lymph node enlargement is observed in various diseases, including malignant lymphoma (ML). Open biopsy of the enlarged lymph node is frequently required for diagnosis, especially when ML is suspected. Serum levels of soluble interleukin 2 receptor (sIL-2R) may be useful as a biomarker of ML. This study aimed to determine whether the measurement of serum sIL-2R levels might be useful to diagnose ML.

Materials and Methods We retrospectively reviewed the data of 281 patients who had undergone open cervical lymph node biopsy at our institution between 2015 and 2019, including 157 males and 124 females (age range, 5–90 years). Data on the patients' age, final diagnosis, and serum sIL-2R levels were obtained from their medical records.

Results Overall, 184 cases of MLs and 97 cases of other diseases (non-MLs [NMLs]) were recorded. The mean age was significantly higher and mean serum sIL-2R levels were significantly higher in the ML group than in the NML group. In the ML group, the serum sIL-2R levels were significantly higher in patients with T cell lymphoma than in those with B cell lymphoma. The area under the receiver operating characteristic curve of the serum sIL-2R level for predicting ML was 0.711, and a serum sIL-2R level of 1,246 U/mL was associated with the maximum value of the sensitivity + specificity for the diagnosis of ML. Multivariate analysis revealed that the area under the receiver operating characteristic curve increased to 0.758 for patients aged >61 years and patients with serum sIL-2R levels of >1,246 U/mL.

Conclusions Among patients presenting with cervical lymphadenopathy, the measurement of serum sIL-2R levels could be useful for distinguishing between patients with and without ML, with a cutoff level of 1,246 U/mL for the diagnosis of ML.

Keywords

cervical lymph node swelling - open biopsy - sIL-2R - malignant lymphoma


Publication History

Received: 30 May 2022

Accepted: 03 March 2023

Article published online:
18 June 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Rubin LA, Kurman CC, Fritz ME. et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135 (05) 3172-3177
    CrossrefPubMedGoogle Scholar
  • 2 Diamantstein T, Osawa H, Mouzaki A, Josimovic-Alasevic O. Regulation of interleukin-2 receptor expression and receptor release. Mol Immunol 1986; 23 (11) 1165-1172
    CrossrefPubMedGoogle Scholar
  • 3 Zerler B. The soluble interleukin-2 receptor as a marker for human neoplasia and immune status. Cancer Cells 1991; 3 (12) 471-479
    PubMedGoogle Scholar
  • 4 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48 (03) 452-458
    Google Scholar
  • 5 Pizzolo G, Chilosi M, Vinante F. et al. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer 1987; 55 (04) 427-428
    CrossrefPubMedGoogle Scholar
  • 6 Sakai A, Yoshida N. The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas. J Clin Exp Hematop 2014; 54 (01) 49-57
    CrossrefPubMedGoogle Scholar
  • 7 Nakase K, Tsuji K, Tamaki S. et al. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev 2005; 29 (03) 256-259
    CrossrefPubMedGoogle Scholar
  • 8 Takahashi S, Setoguchi Y, Nukiwa T, Kira S. Soluble interleukin-2 receptor in sera of patients with pulmonary tuberculosis. Chest 1991; 99 (02) 310-314
    CrossrefPubMedGoogle Scholar
  • 9 Karim AF, Eurelings LEM, Bansie RD, van Hagen PM, van Laar JAM, Dik WA. Soluble interleukin-2 receptor: a potential marker for monitoring disease activity in IgG4-related disease. Mediators Inflamm 2018; 2018: 6103064
    CrossrefPubMedGoogle Scholar
  • 10 Seidler S, Zimmermann HW, Weiskirchen R, Trautwein C, Tacke F. Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes. BMC Gastroenterol 2012; 12: 38
    CrossrefPubMedGoogle Scholar
  • 11 Eurelings LEM, Miedema JR, Dalm VASH. et al. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS One 2019; 14 (10) e0223897
    CrossrefPubMedGoogle Scholar
  • 12 Dumas G, Prendki V, Haroche J. et al. Kikuchi-Fujimoto disease: retrospective study of 91 cases and review of the literature. Medicine (Baltimore) 2014; 93 (24) 372-382
    CrossrefPubMedGoogle Scholar
  • 13 Murakami J, Arita K, Wada A. et al. Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions. Mol Clin Oncol 2019; 11 (05) 474-482
    PubMedGoogle Scholar
  • 14 Hamon MD, Unal E, Macdonald I, Shamim F, Boesen E, Prentice HG. Plasma soluble interleukin 2 receptor levels in patients with malignant lymphoma are correlated with disease activity but not cellular immunosuppression. Leuk Lymphoma 1993; 10 (1-2): 111-115
    CrossrefPubMedGoogle Scholar
  • 15 van Rhee F, Voorhees P, Dispenzieri A. et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018; 132 (20) 2115-2124
    CrossrefPubMedGoogle Scholar
  • 16 Hornef MW, Wagner HJ, Kruse A, Kirchner H. Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo. Clin Diagn Lab Immunol 1995; 2 (02) 209-213
    CrossrefPubMedGoogle Scholar
  • 17 Matsuda J, Gotoh M, Gohchi K, Tsukamoto M, Saitoh N, Kinoshita T. Clinical significance of serum 2,5-oligoadenylate synthetase and soluble interleukin-2 receptor in hemophiliacs positive and negative for human immunodeficiency virus type 1. Clin Diagn Lab Immunol 1994; 1 (02) 155-159
    CrossrefPubMedGoogle Scholar
  • 18 Kuroda K, Kashiwagi S, Teraoka H. et al. Kimura's disease affecting the axillary lymph nodes: a case report. BMC Surg 2017; 17 (01) 63
    CrossrefPubMedGoogle Scholar